Meeting slides
Interactive presentation

How has the BA.2.12.1 COVID-19 subvariant changed clinical practice?

As Omicron subvariants continue to emerge, clinical practice must quickly shift to optimally manage nonhospitalized patients with mild to moderate COVID-19. The current Omicron subvariants have left only 1 anti-SARS-CoV-2 monoclonal antibody for pre-exposure prophylaxis and 1 for treatment. Drs. Lucy Horton and Monica Gandhi discuss what they are doing to incorporate both antivirals and anti-SARS-
Interactive presentation

Real-World Best Practices in a COVID-19 Clinic

Drs Monica Gandhi and Lucy Horton discuss eligibility for anti-SARS-CoV-2 monoclonal antibodies for both treatment and pre-exposure prophylaxis as well as clinic models to deliver these as safely and efficiently as possible. Faculty also discuss optimal strategies to overcome disparities in care for COVID-19 testing, monoclonal antibodies, and oral antivirals.
Suggested Readings

Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19.

Bierle DM, Ganesh R, Wilker CG, et al. J Prim Care Community Health. 2021;12:21501327211019282.

Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19.

Dougan M, Azizad M, Chen P, et al. medRxiv. 2022. [Epub ahead of print]

Neutralization escape by the SARS-CoV-2 Omicron variants BA.2.12.1 and BA.4/BA.5.

Hachmann NP, Miller J, Collier A-rY, et al. medRxiv. 2022. [Epub ahead of print]

At the heart of the matter: unmasking and addressing the toll of COVID-19 on diverse populations.

Haynes N, Cooper LA, Albert MA. Circulation. 2020;142(2):105-107.

Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19.

Levin M, Ustianowski A, De Wit S, et al. N Engl J Med. 2022. [Epub ahead of print]

Racial and ethnic disparities in receipt of medications for treatment of COVID-19—United States, March 2020-August 2021.

Wiltz JL, Feehan AK, Molinari NM, et al. MMWR Morb Mortal Wkly Rep. 2022;71(3):96-102.

Disparities in COVID-19 monoclonal antibody delivery: a retrospective cohort study.

Wu EL, Kumar RN, Moore WJ, et al. J Gen Intern Med. 2022:1-9.

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants.

Yu J, Collier A-RY, Rowe M, et al. N Engl J Med. 2022;386(16):1579-1580.

Related activities
POC101 
0.25 CME/CE

Current Evidence and Guidelines for Anti-SARS-CoV-2 Monoclonal Antibodies

Module 1

Faculty: Monica Gandhi, MD, MPH; Lucy Horton, MD, MPH
Release: 06/07/2022
Expiration: 06/07/2023
POC101 
0.25 CME/CE

Real-World Use of Anti-SARS-CoV-2 Monoclonal Antibodies

Module 2

Faculty: Monica Gandhi, MD, MPH; Lucy Horton, MD, MPH
Release: 06/07/2022
Expiration: 06/07/2023